Last reviewed · How we verify

Fosamax

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · FDA-approved active Small molecule Quality 2/100

Fosamax is a Small molecule drug developed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. It is currently FDA-approved. Also known as: alendronate sodium, Alendronate sodiuum.

At a glance

Generic nameFosamax
Also known asalendronate sodium, Alendronate sodiuum
SponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fosamax

What is Fosamax?

Fosamax is a Small molecule drug developed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

Who makes Fosamax?

Fosamax is developed and marketed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (see full Xinhua Hospital, Shanghai Jiao Tong University School of Medicine pipeline at /company/xinhua-hospital-shanghai-jiao-tong-university-school-of-medicine).

Is Fosamax also known as anything else?

Fosamax is also known as alendronate sodium, Alendronate sodiuum.

What development phase is Fosamax in?

Fosamax is FDA-approved (marketed).

Related